Form 4: Phathom Director Gifts Shares to Spouse's Trust

Phathom Pharmaceuticals Director Asit Parikh transferred 80,500 shares of common stock to a trust for his spouse, maintaining indirect beneficial ownership.

Summary

• Director Asit Parikh transferred 80,500 shares of Phathom Pharmaceuticals, Inc. common stock on January 23, 2026.
• The transfer was a gift for no consideration ($0 price) to a trust established for the benefit of his spouse.
• Mr. Parikh serves as the trustee of this trust, maintaining indirect beneficial ownership of the transferred shares.
• Following the transaction, Mr. Parikh directly owns 50,500 shares and indirectly owns 80,500 shares through the trust.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• The 80,500 shares transferred to the trust are subject to a lock-up agreement dated January 7, 2026, which the trust has agreed to uphold.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction for estate planning purposes, not indicative of company performance or significant change in beneficial ownership control.

Future Outlook

NA

Industry Context

This filing details a routine insider transaction for estate planning purposes and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• Asit Parikh, a director, transferred 80,500 shares to a trust for the benefit of his spouse, for which he also serves as trustee. This constitutes a related party transaction due to the familial relationship and his role as trustee.

Stakeholder Impact

• Minimal direct impact on shareholders as the beneficial ownership remains with the director's family, and the shares are subject to a lock-up agreement, limiting immediate market impact.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a non-market transaction (a gift to a family trust) by a director, which does not reflect a change in the director's overall investment conviction or the company's operational performance. The shares remain beneficially owned by the director's family and are subject to a lock-up, indicating no immediate selling pressure. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Phathom Pharmaceuticals, PHAT, Asit Parikh, Insider Transaction, Form 4, Stock Transfer, Trust, Director, Gift, 10b5-1 plan, Lock-up Agreement